Tech Company Financing Transactions
Ember Therapeutics Funding Round
Ember Therapeutics, based in New York, secured $34 million in investment from Third Rock Ventures.
Transaction Overview
Company Name
Announced On
12/15/2011
Transaction Type
Venture Equity
Amount
$34,000,000
Round
Series A
Investors
Third Rock Ventures (Lou Tartaglia)
Proceeds Purpose
Third Rock Ventures, LLC today announced the formation of Ember Therapeutics. The company was launched with a $34 million Series A financing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 World Trade Center 85th Floor
New York, NY 10007
USA
New York, NY 10007
USA
Phone
Undisclosed
Website
Email Address
Overview
Ember Therapeutics is a clinical stage therapeutic company focusing on Bone Morphogenetic Protein-7 (BMP-7) and its role in Osteoarthritis (OA) and organ fibrosis, including Chronic Kidney Disease (CKD) and Alport s Syndrome.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Joseph Hernandez
Vice President
Hyun Kim
Browse more venture capital transactions:
Prev: 12/15/2011: Cerulean Pharma venture capital transaction
Next: 12/16/2011: MediaBrix venture capital transaction
Share this article
News on VC Transactions
We document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs